SLS SELLAS Life Sciences Group Inc. Expected net earnings per share growth this year
SELLAS Life Sciences develops advanced peptide immunotherapies to combat oncology, actively investing in the GPS platform. The annual earnings per share trajectory, illustrated by this chart on GURU.Markets, contains the mark 18.20, indicating the level of EPS dynamics. However, the narrow pipeline focus creates binary risks, and the retention of scientific staff is based solely on faith in the success of the developments.
Financial and market metric breakdowns for sellaslifesciences.com (SLS)
- stock value and consensus price forecast:
- market capitalization data:
- shareholders' equity book value data:
- debt burden and liquidity indicators:
Debt to Equity SELLAS Life Sciences|SLS - Long-Term Debt to Capital|Short-Term Debt to Capital SELLAS Life Sciences Group|SLS - Company Debts|Debts to Net Assets SELLAS Life Sciences|SLS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings SELLAS Life Sciences|Quick Liquidity sellaslifesciences.com
- company profitability and valuation multiples indicators:
SLS - Net Profit|Company Profit Forecast SELLAS Life Sciences|SLS - P/E Multiple|Price to Expected Earnings Ratio SELLAS Life Sciences Group|SLS - PEG Multiple|Company Value to EBITDA SELLAS Life Sciences|SLS - Operating profit before deduction of amortization|Earnings per share for the trailing year SELLAS Life Sciences|SLS - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months sellaslifesciences.com|SLS - Earnings growth in current year|Expected earnings per share growth for next year SELLAS Life Sciences
Basic company analysis:SLS - SELLAS Life Sciences Group Inc.
For the biopharmaceutical sector, SELLAS Life Sciences (SLS) utilizes measured YoY EPS growth as an indicator of the company's ability to convert large-scale investments in the GPS platform into actual shareholder value. This metric's price action reflects the percentage change in net income per share relative to the previous year, allowing investors to assess capital management efficiency against the backdrop of intensive R&D expenditures.
Key competitors
Earnings per share growth rate in current year BeiGene Ltd. (ONC)|Earnings per share growth in current year Halozyme Inc.|Revolution Medicines Corp (RVMD) - Expected net earnings per share growth this year|Earnings growth in current year AAPG|CGON - Earnings per share growth rate in current year|Earnings per share growth in current year UroGen Pharma URGN|Bicara Therapeutics Inc - Earnings per share growth in current year|PSNL - Earnings per share growth in current year|ERAS: Earnings per share growth in current year|DCTH: Earnings growth in current year|ymabs.com (YMAB) - Earnings growth in current year|Earnings per share growth in current year Aura Biosciences|Candel (CADL) - Expected net earnings per share growth this year|Net earnings per share growth this year ARAY (Accuray Inc.)|ACTU (Actuate Therapeutics Inc) - Earnings per share increase in current year|Earnings per share growth in current year Citius Oncology, Inc. CTOR|TuHURA Biosciences Inc. - Earnings per share growth in current year|Protara Therapeutics, Inc. - Earnings growth in current year|Expected net earnings per share growth this year Fate Therapeutics Inc FATE|WHWK: Earnings growth in current year|Earnings per share trend in current year TCRX (TScan Therapeutics, Inc.)|CSBR (Champions Oncology Inc) - Earnings growth in current year|Earnings per share growth rate in current year XBiotech USA XBIT|Net earnings per share growth this year CVM (CEL-SCI Corporation)|OSTX (OS Therapies Inc.) - Earnings per share increase in current year|Earnings per share growth in current year Radiopharm Theranostics RADX|Expected net earnings per share growth this year Artiva Biotherapeutics Inc. (ARTV)|Adlai Nortye Limited - Earnings growth in current year|verupharma.com (VERU) - Net earnings per share growth this year|TPST: Earnings growth in current year|XLO - Expected net earnings per share growth this year|RENB (Renovaro Biosciences) - Earnings growth in current year|Earnings per share growth rate in current year Mural Bio MURA|Earnings per share growth in current year Kairos Pharma Ltd (KAPA)|onkuretherapeutics.com - Earnings per share growth this year|Earnings growth in current year GDTC (CytoMed Therapeutics Limited)|CRIS - Net earnings per share growth this year|Apollomics Corp - Earnings growth in current year|Earnings per share growth rate in current year Tharimmune Corporation|advanbiomed.com (ADVB) - Earnings per share growth in current year|GNPX - Expected net earnings per share growth this year|Earnings per share growth in current year Calidi Biotherapeutics Inc.|sunshinebiopharma.com (SBFM) - Expected net earnings per share growth this year|Earnings per share growth in current year Xenetic Biosciences (XBIO)|Earnings per share growth in current year SLRX (Salarius Pharma)|Earnings per share growth in current year Purple Biotech PPBT|Expected net earnings per share growth this year American Oncology Network Inc (AONC)|BeiGene - Earnings growth in current year|Checkpoint Therapeutics Inc. (CKPT) - Net earnings per share growth this year|ELEV: Earnings growth in current year|iCAD (ICAD) - Earnings growth in current year|Earnings per share growth in current year Ikena Oncology Inc.|Earnings per share growth this year NTBL (notablelabs.com)|Earnings growth in current year VIRX|Net earnings per share growth this year MorphoSys Inc MOR|Earnings growth in current year NAYA (NAYA Bio)|Ascentage (AAPGV) - Earnings per share growth rate in current year
